SELLAS Life Sciences
28 hedge funds and large institutions have $4.32M invested in SELLAS Life Sciences in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 7 closing their positions.
2,721% more call options, than puts
Call options by funds: $2M | Put options by funds: $71K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
0% more funds holding
Funds holding: 28 → 28 (0)
2% less capital invested
Capital invested by funds: $4.42M → $4.32M (-$99.7K)
1.75% less ownership
Funds ownership: 10.65% → 8.89% (-1.8%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$155K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$122K |
| 3 |
Millennium Management
New York
|
+$102K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.8K |
| 5 |
OCG
Opus Capital Group
Cincinnati,
Ohio
|
+$55.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$292K |
| 2 |
HCM
Highbridge Capital Management
New York
|
-$202K |
| 3 |
Two Sigma Investments
New York
|
-$108K |
| 4 |
Renaissance Technologies
New York
|
-$45K |
| 5 |
JP Morgan Chase
New York
|
-$7K |
SLS Hedge Fund Activity: Q4 2022 in Review
28 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q4 2022, worth a combined $4.32M — down 2.3% from $4.42M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SLS positions and 7 closed out — a net gain of 1 holder — while 9 added to existing stakes and 5 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $155K. The largest seller was Citadel Advisors, cutting an estimated $292K.
- 28 institutional investors held SELLAS Life Sciences (SLS) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $4.32M of SELLAS Life Sciences stock for Q4 2022, down 2.3% quarter-over-quarter.
- 8 funds opened new SELLAS Life Sciences positions in Q4 2022 and 7 closed out, a net change of +1 holder.
- The largest SELLAS Life Sciences buyer in Q4 2022 was XTX Topco, an estimated $155K added.
- The largest SELLAS Life Sciences seller in Q4 2022 was Citadel Advisors, an estimated $292K sold.
Based on aggregated 13F filings for Q4 2022.